Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 61.48
+1.27 (2.11%)
At close: Mar 27, 2026
31.20% (1Y)
| Assets | 39.09M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +31.20% |
| Volume | 212 |
| Open | 61.00 |
| Previous Close | 60.21 |
| Day's Range | 61.00 - 61.56 |
| 52-Week Low | 38.76 |
| 52-Week High | 65.95 |
| Beta | 0.35 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 31.20% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.39%.
Top Holdings
12.60% of assets| Name | Symbol | Weight |
|---|---|---|
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.42% |
| TG Therapeutics, Inc. | TGTX | 1.34% |
| Alkermes plc | ALKS | 1.27% |
| Protagonist Therapeutics, Inc. | PTGX | 1.25% |
| Insmed Incorporated | INSM | 1.25% |
| Apogee Therapeutics, Inc. | APGE | 1.24% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.23% |
| Scholar Rock Holding Corporation | SRRK | 1.20% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 1.20% |
| Neurocrine Biosciences, Inc. | NBIX | 1.20% |